Negative results in recent trials have highlighted the challenges that newer genomic test makers must overcome in proving methods for personalized CUP treatment.
A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.
At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.
The method allows for the annotation of cells by their genotype and capture of single-cell transcriptomes, even when the cells aren't morphologically distinct.
St. Jude investigators are sharing their WGS cancer data through the St. Jude Cloud, as well as tools and pipelines to help other researchers analyze and use it.
The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.
